Het Radboudumc of voluit Radboud universitair medisch centrum is een academisch ziekenhuis in Nijmegen dat samenwerkt met de Radboud Universiteit. Het maakt deel uit van de Nederlandse Federatie van Universitair Medische Centra. Het ziekenhuis heeft in 2019 1065 bedden en bijna 11.000 medewerkers.

During the past decade, Radboud University Nijmegen Medical Centre conducted 126 clinical trials. In the 10-year time frame, 126 clinical trials started and 46 clinical trials were completed, i.e. on average, 36.5% percent of trials that started reached the finish line to date. In the past 5 years, 56 clinical trials started and 28 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Radboud University Nijmegen Medical Centre" #1 sponsor was "Radboud University Medical Center" with 149 trials, followed by "European Organisation for Research and Treatment of Cancer - EORTC" with 61 trials sponsored, "Pfizer" with 11 trials sponsored, "Vertex Pharmaceuticals Incorporated" with 10 trials sponsored and "The Netherlands Cancer Institute" with 10 trials sponsored. Other sponsors include 155 different institutions and companies that sponsored additional 103 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Radboud University Nijmegen Medical Centre" #1 collaborator was "ZonMw: The Netherlands Organisation for Health Research and Development" with 29 trials as a collaborator, "Radboud University Medical Center" with 19 trials as a collaborator, "Dutch Cancer Society" with 14 trials as a collaborator, "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)" with 7 trials as a collaborator and "AstraZeneca" with 6 trials as a collaborator. Other collaborators include 302 different institutions and companies that were collaborators in the rest 224 trials.

According to Clinical.Site data, the most researched conditions in "Radboud University Nijmegen Medical Centre" are "Breast Cancer" (12 trials), "Leukemia" (11 trials), "Colorectal Cancer" (10 trials), "Cystic Fibrosis" (10 trials) and "Prostate Cancer" (9 trials). Many other conditions were trialed in "Radboud University Nijmegen Medical Centre" in a lesser frequency.

Most popular intervention types in "Radboud University Nijmegen Medical Centre" are "Drug" (228 trials), "Other" (51 trials), "Procedure" (45 trials), "Biological" (40 trials) and "Radiation" (27 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (46 trials), "radiation therapy" (14 trials), "IVA" (10 trials), "cisplatin" (10 trials) and "cyclophosphamide" (7 trials). Other intervention names were less common.

The vast majority of trials in "Radboud University Nijmegen Medical Centre" are 336 trials for "All" genders, 41 trials for "Male" genders and 23 trials for "Female" genders.

Currently, there are 63 active trials in "Radboud University Nijmegen Medical Centre". 1 are not yet recruiting, 42 are recruiting, 16 are Active, not recruiting, and 4 are Enrolling by invitation. In total, there were 231 completed trials in Radboud University Nijmegen Medical Centre, 4 suspended trials, and 36 terminated clinical trials to date.

Out of the total trials that were conducted in Radboud University Nijmegen Medical Centre, 43 "Phase 1" clinical trials were conducted, 86 "Phase 2" clinical trials and 112 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 29 trials, and there were also 95 trials that are defined as “Not Applicable".